Literature DB >> 17380197

Medical applications of leukocyte surface molecules--the CD molecules.

Heddy Zola1.   

Abstract

Leukocytes are the cells of the immune system and are centrally involved in defense against infection, in autoimmune disease, allergy, inflammation, and in organ graft rejection. Lymphomas and leukemias are malignancies of leukocytes, and the immune system is almost certainly involved in most other cancers. Each leukocyte expresses a selection of cell surface glycoproteins and glycolipids which mediate its interaction with antigen, with other components of the immune system, and with other tissues. It is therefore not surprising that the leukocyte surface molecules (CD molecules) have provided targets for diagnosis and therapy. Among the "celebrities" are CD20, a target for lymphoma therapeutic antibodies which earns $2 billion annually (and makes a significant difference to lymphoma patients), and CD4, the molecule used by the human immunodeficiency virus (HIV) as an entry portal into cells of the immune system. This short review provides a background to the CD molecules and antibodies against them, and summarizes research, diagnostic, and therapeutic applications of antibodies against these molecules.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17380197      PMCID: PMC1829200          DOI: 10.2119/2006–00081.Zola

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  42 in total

1.  A Phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma.

Authors:  M L Grossbard; P S Multani; A S Freedman; S O'Day; J G Gribben; C Rhuda; D Neuberg; L M Nadler
Journal:  Clin Cancer Res       Date:  1999-09       Impact factor: 12.531

2.  The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.

Authors:  Jessica L Teeling; Wendy J M Mackus; Luus J J M Wiegman; Jeroen H N van den Brakel; Stephen A Beers; Ruth R French; Tom van Meerten; Saskia Ebeling; Tom Vink; Jerry W Slootstra; Paul W H I Parren; Martin J Glennie; Jan G J van de Winkel
Journal:  J Immunol       Date:  2006-07-01       Impact factor: 5.422

3.  Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes.

Authors:  Shelley Lindley; Colin M Dayan; Amanda Bishop; Bart O Roep; Mark Peakman; Timothy I M Tree
Journal:  Diabetes       Date:  2005-01       Impact factor: 9.461

Review 4.  Current status and perspective of antibody therapy in follicular lymphoma.

Authors:  Christian Buske; Oliver Weigert; Martin Dreyling; Michael Unterhalt; Wolfgang Hiddemann
Journal:  Haematologica       Date:  2006-01       Impact factor: 9.941

5.  Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthrax.

Authors:  Johnny W Peterson; Jason E Comer; David M Noffsinger; Autumn Wenglikowski; Kristin G Walberg; Bagram M Chatuev; Ashok K Chopra; Lawrence R Stanberry; Angray S Kang; Wolfgang W Scholz; Jagadish Sircar
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

6.  Characterisation of the protein composition of peripheral blood mononuclear cell microsomes by SDS-PAGE and mass spectrometry.

Authors:  Ian C Nicholson; Chris Mavrangelos; Kim Fung; Mustafa Ayhan; Ilya Levichkin; Amelia Johnston; Heddy Zola; Nicholas J Hoogenraad
Journal:  J Immunol Methods       Date:  2005-08-16       Impact factor: 2.303

7.  Large B-cell lymphoma with Hodgkin's features.

Authors:  J F García; M Mollejo; M Fraga; J Forteza; J A Muniesa; M Pérez-Guillermo; C Pérez-Seoane; T Rivera; P Ortega; M A Piris
Journal:  Histopathology       Date:  2005-07       Impact factor: 5.087

8.  Phase I clinical trial of serotherapy in patients with acute myeloid leukemia with an immunoglobulin M monoclonal antibody to CD15.

Authors:  E D Ball; K Selvaggi; D Hurd; R Herzig; L Clark; V Malley; J Persichetti; M deMagelhaus-Silverman
Journal:  Clin Cancer Res       Date:  1995-09       Impact factor: 12.531

9.  Phase Ia trial of murine immunoglobulin A antitransferrin receptor antibody 42/6.

Authors:  D Brooks; C Taylor; B Dos Santos; H Linden; A Houghton; T T Hecht; S Kornfeld; R Taetle
Journal:  Clin Cancer Res       Date:  1995-11       Impact factor: 12.531

10.  CD molecules 2005: human cell differentiation molecules.

Authors:  Heddy Zola; Bernadette Swart; Ian Nicholson; Bent Aasted; Armand Bensussan; Laurence Boumsell; Chris Buckley; Georgina Clark; Karel Drbal; Pablo Engel; Derek Hart; Václav Horejsí; Clare Isacke; Peter Macardle; Fabio Malavasi; David Mason; Daniel Olive; Armin Saalmueller; Stuart F Schlossman; Reinhard Schwartz-Albiez; Paul Simmons; Thomas F Tedder; Mariagrazia Uguccioni; Hilary Warren
Journal:  Blood       Date:  2005-07-14       Impact factor: 22.113

View more
  16 in total

1.  CD38 and CD157: biological observations to clinical therapeutic targets.

Authors:  Amy Warenda Czura; Christopher J Czura
Journal:  Mol Med       Date:  2006 Nov-Dec       Impact factor: 6.354

2.  A framework for analytical characterization of monoclonal antibodies based on reactivity profiles in different tissues.

Authors:  Elizabeth Rossin; Tsung-I Lin; Hsiu J Ho; Steven J Mentzer; Saumyadipta Pyne
Journal:  Bioinformatics       Date:  2011-08-16       Impact factor: 6.937

3.  Does computational biology help us to understand the molecular phylogenetics and evolution of cluster of differentiation (CD) proteins?

Authors:  Chiranjib Chakraborty; C George Priya Doss; Ritu Sharma; Subrata Sahana; Thumpi S Nair
Journal:  Protein J       Date:  2013-02       Impact factor: 2.371

4.  Surgically resected human tumors reveal the biological significance of the gastric cancer stem cell markers CD44 and CD26.

Authors:  Shimpei Nishikawa; Masamitsu Konno; Atsushi Hamabe; Shinichiro Hasegawa; Yoshihiro Kano; Takahito Fukusumi; Taroh Satoh; Shuji Takiguchi; Masaki Mori; Yuichiro Doki; Hideshi Ishii
Journal:  Oncol Lett       Date:  2015-03-20       Impact factor: 2.967

5.  Mass-spectrometric identification and relative quantification of N-linked cell surface glycoproteins.

Authors:  Bernd Wollscheid; Damaris Bausch-Fluck; Christine Henderson; Robert O'Brien; Miriam Bibel; Ralph Schiess; Ruedi Aebersold; Julian D Watts
Journal:  Nat Biotechnol       Date:  2009-04-06       Impact factor: 54.908

6.  Markers and methods for cell sorting of human embryonic stem cell-derived neural cell populations.

Authors:  Jan Pruszak; Kai-Christian Sonntag; Moe Hein Aung; Rosario Sanchez-Pernaute; Ole Isacson
Journal:  Stem Cells       Date:  2007-06-21       Impact factor: 6.277

7.  CD15, CD24, and CD29 define a surface biomarker code for neural lineage differentiation of stem cells.

Authors:  Jan Pruszak; Wesley Ludwig; Alexandra Blak; Kambiz Alavian; Ole Isacson
Journal:  Stem Cells       Date:  2009-12       Impact factor: 6.277

8.  Neurotherapeutic effect of cord blood derived CD45+ hematopoietic cells in mice after traumatic brain injury.

Authors:  Hadar Arien-Zakay; Galit Gincberg; Arnon Nagler; Gadi Cohen; Sigal Liraz-Zaltsman; Victoria Trembovler; Alexander G Alexandrovich; Ilan Matok; Hanan Galski; Uriel Elchalal; Peter I Lelkes; Philip Lazarovici; Esther Shohami
Journal:  J Neurotrauma       Date:  2014-07-14       Impact factor: 5.269

9.  Proline rich motifs as drug targets in immune mediated disorders.

Authors:  Mythily Srinivasan; A Keith Dunker
Journal:  Int J Pept       Date:  2012-05-16

10.  Highly pure and expandable PSA-NCAM-positive neural precursors from human ESC and iPSC-derived neural rosettes.

Authors:  Dae-Sung Kim; Dongjin R Lee; Han-Soo Kim; Jeong-Eun Yoo; Sung Jun Jung; Bo Young Lim; Jiho Jang; Hoon-Chul Kang; Seungkwon You; Dong-Youn Hwang; Joong Woo Leem; Taick Sang Nam; Sung-Rae Cho; Dong-Wook Kim
Journal:  PLoS One       Date:  2012-07-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.